KRAS and neoplasm: To date, although TSAs and tumor neoantigens are the ideal antigens for developing efficient CAR T cells, only a few TSAs in their true sense have been reported, such as BRAF, KRAS, TP53, HRAS/KRAS/NRAS, and BRAF [63].